Once a day Concerta methylphenidate was equivalent to 3 times daily methylphenidate in children with ADHD

Daniel F. Connor
University of Massachusetts Medical School

Follow this and additional works at: http://escholarship.umassmed.edu/oapubs

Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Psychiatry and Psychology Commons

Repository Citation
Connor, Daniel F., "Once a day Concerta methylphenidate was equivalent to 3 times daily methylphenidate in children with ADHD" (2002). Open Access Articles. Paper 560.
http://escholarship.umassmed.edu/oapubs/560

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Once a day Concerta methylphenidate was equivalent to 3 times daily methylphenidate in children with ADHD

Daniel Connor

Evid. Based Ment. Health 2002;5;20-

Updated information and services can be found at:
http://ebmh.bmj.com/cgi/content/full/5/1/20

These include:

Rapid responses
You can respond to this article at:
http://ebmh.bmj.com/cgi/eletter-submit/5/1/20

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Child and adolescent psychiatry (320 articles)
Drugs: psychiatry (441 articles)

Notes

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to Evidence-Based Mental Health go to:
http://journals.bmj.com/subscriptions/
Once a day Concerta methylphenidate was equivalent to 3 times daily methylphenidate in children with ADHD


QUESTION: In children with attention deficit hyperactivity disorder (ADHD), is once daily extended release methylphenidate (MPH) as effective as 3 times daily dosing?

Design
Randomised (unclear allocation concealment8), blinded (patients/parents and outcome assessors), placebo controlled crossover trial with 7 days of follow up for each treatment condition.

Setting
State University of New York at Buffalo, Buffalo, New York, USA.

Patients
70 children between 6 and 12 years of age (mean age 9 y, 89% boys) with ADHD receiving a stable dose of MPH for ≥4 weeks. Exclusion criteria included contraindication to stimulant medication, any condition that would interfere with participation in laboratory classroom assessment, receiving any other medication for ADHD, and having reached menarche. 2 children were discontinued from the study.

Intervention
Crossover comparison of placebo, immediate release (IR) MPH 3 times a day (tid), and Concerta, a once daily MPH formulation taken in the morning. Each child’s dose concentration was based on that child’s MPH dosing before the study. 3 dosing concentrations of medication were used: 5 mg IR MPH tid/18 mg Concerta once a day; 10 mg IR MPH tid/50 mg Concerta once a day; and 15 mg IR MPH tid/54 mg Concerta once a day. Children received each medication condition for 7 days. Parents received behavioural parent training and teachers were taught to establish a school home daily report card.

Main outcome measures
Change in ADHD symptoms, social behaviour and academic performance in both naturalistic (home and school) and laboratory environments (on Saturday); and side effects.

Main results
On all measures in all settings, both drug conditions were statistically different from placebo (p < 0.001 for all measures) with little difference between drug conditions. In the natural setting, effect sizes (magnitude of the drug effects relative to placebo) on ADHD symptoms were 2.0, on oppositional defiant disorder symptoms 1.5, and on peer relation problems 1.4. Both medications improved behaviour as measured by teacher ratings and individualised target behaviours. These effects continued on into the evening as measured by parent ratings. In the laboratory setting Concerta was equivalent to IR MPH and both were statistically different from placebo. Effect sizes for both active drugs ranged from 0.4 to 0.8 on measures of rule violation frequency, negative behaviour frequency, observed disruptive behaviours, and individualised target behaviours. Side effects on children’s sleep and appetite were similar for the 2 drug conditions.

Conclusion
Once a day Concerta methylphenidate was equivalent to 3 times daily methylphenidate in children with attention deficit hyperactivity disorder.

*See glossary.

COMMENTARY
This study by Pelham et al addresses several important questions in the clinical pharmacological treatment of children with ADHD. Firstly, it is well known that IR stimulants have a short duration of effect, leaving the ADHD child vulnerable to breakthrough symptoms as plasma stimulant concentrations decline before the next dose. Secondly, IR stimulants require multiple daily dosings, increasing the risk of medication non-compliance, especially when the ADHD child must visit the nurse during the school day. Thirdly, when given twice daily (the previous standard of care) the short duration of action of IR stimulants results in after school and early evening hours where the child’s ADHD is not supported by stimulant medication. Thus, more recent recommendations have favoured 3 times daily dosing for IR stimulants such as methylphenidate.

The main conclusion of this study is that once daily Concerta, a long acting MPH formulation, is equivalent to MPH 3 times a day, and both medications are better than placebo for symptoms of ADHD. On a multiplicity of measures assessing ADHD symptoms, ADHD child, parent and teacher observers and data from a laboratory school, improvement on ADHD symptoms was documented for both active drug conditions. With the exception of 2 parent ratings, no differences were found on outcome measures across the IR MPH and Concerta drug conditions, showing that once daily Concerta was equivalent to standard 3 times daily MPH treatment.

One issue that needs to be considered in evaluating the findings is that medication was given in the context of ongoing behavioural treatment given to the child’s parents and teachers in the laboratory school. Although given across all 3 conditions (Concerta, MPH, and placebo), children in this study were receiving combined behavioural and pharmacological treatment. That combined treatment may not be available to ADHD children in the “real world” of clinical practice needs to be noted.

The potential for effective, once daily, long acting stimulants such as Concerta to become the standard of care in the pharmacological treatment of ADHD is supported by the results of this study. Equal efficacy to IR stimulants which need to be given multiple times daily, with the potential for increased compliance and ease of use clearly makes long acting stimulants important in the clinician’s ADHD armamentarium.

Daniel Connor, M.D.
University of Massachusetts Medical School
Worcester, Massachusetts, USA